Jon Cronin, MD
Internal Medicine · Milton, MANPI 1326085523
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 67 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $545 and has fallen 88.5% since, to $63 in 2025.
Across 67 payments — averaging $22.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$230
- Pfizer$160
- Boehringer Ingelheim$136
- Novo Nordisk$125
- Amgen$88
- Boston Scientific$85
- plus $716 from 17 others
Across 4 payments — averaging $5526.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kowa Research Institute, Inc.$22K
What the payments were for
- Food & beverage$1,540100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 9 | $230 |
| Pfizer | 7 | $160 |
| Boehringer Ingelheim | 5 | $136 |
| Novo Nordisk | 6 | $125 |
| Amgen | 4 | $88 |
| Boston Scientific | 1 | $85 |
| AstraZeneca | 4 | $78 |
| Merck | 4 | $67 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $65 |
| Bayer | 3 | $55 |
| GSK | 3 | $52 |
| Amarin Pharma, Inc. | 4 | $51 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $50 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Novartis | 3 | $42 |
| Kestra Medical Technology Services, Inc. | 1 | $40 |
| Heartflow, Inc. | 1 | $34 |
| Johnson & Johnson | 1 | $30 |
| Bridgebio Pharma, Inc. | 1 | $26 |
| Abbott | 1 | $26 |
| Irhythm Technologies, Inc. | 1 | $21 |
| Edwards Lifesciences | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
How this compares
$1,540 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 554 | $524,910 |
| JanuviaSitagliptin Phosphate | 115 | $121,576 |
| XareltoRivaroxaban | 84 | $92,000 |
| JardianceEmpagliflozin | 66 | $55,161 |
| OzempicSemaglutide | 32 | $33,949 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $31,594 |
| EntrestoSacubitril/Valsartan | 19 | $22,472 |
| Repatha SureclickEvolocumab | 20 | $20,344 |
| WegovySemaglutide | 13 | $18,412 |
| Metoprolol Succinate | 685 | $17,249 |
| LyricaPregabalin | 13 | $15,203 |
| Atorvastatin Calcium | 890 | $14,532 |
| Rosuvastatin Calcium | 286 | $12,117 |
| Potassium Chloride | 16 | $8,640 |
| MyrbetriqMirabegron | 12 | $5,507 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Lyrica | $160 | $540,113567 claims |
| MerckJanuvia | $67 | $121,576115 claims |
| Johnson & JohnsonXarelto | $30 | $92,00084 claims |
| Boehringer IngelheimJardiance | $136 | $55,16166 claims |
| Novo NordiskOzempic, Wegovy | $125 | $52,36245 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $52 | $39,80458 claims |
| NovartisEntresto | $42 | $22,47219 claims |
| AstraZenecaSymbicort | $78 | $3,97514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Milton
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.